Fig. 7.

iRGD‐exo loaded with siCPT1A showed better therapeutic efficacy than control‐exo in oxaliplatin‐resistant colon cancer in vivo. (A) A flow diagram of the vivo experimental design. (B) Picture of xenografted tumours from mice after sacrifice (n = 35, 5/per group). (C‐D) Quantitative analysis the weight (C) and volume (D) of tumours (n = 5, mean ± SEM, t‐test). (E‐F) qRT‐PCR (E) and WB (F) quantification of CPT1A tumours in tumours in the different groups. (n = 5, mean ± SEM, t‐test). (G) The expression of CPT1A and Ki‐67 in tissues obtained from the different groups was identified by IHC (scale bar = 1 mm, n = 5). *P < 0.05; **P < 0.01; ***P < 0.001.